The Meta-Analysis of Bevacizumab Combined with Platinum-Based Treatment of Malignant Pleural Effusions by Thoracic Perfusion

Table 1

Basic characteristics of the included studies.

Inclusion in studies	Country	Type of pathology	Staging	Total number of cases	Number of cases in each group		Gender (male/female)	Number of treatment lines	Interventions		Evaluation indicators
					Experimental group	Control group			Experimental group	Control group
Nan Du 2013	China	Non-small-cell lung cancer	IV	70	36	34	39/32	First-line treatment	Cisplatin (60 mg) + bevacizumab (300 mg) dissolved in saline 20 ml by intrathoracic infusion, every 2 weeks, at least two courses of treatment	Cisplatin (60 mg) dissolved in saline 20 ml for intrathoracic instillation	①, ②, ③, ④, ⑤, ⑥, ⑦, ⑧
Liu X.-T. 2017	China	Non-small-cell lung cancer	IV	98	49	49	54/44	First-line treatment	Bevacizumab (5 mg/kg) + cisplatin (45 mg/m^2) was dissolved in 20 mg of 0.9% sodium chloride and injected intrathoracically through a central venous catheter once/week for 3 weeks	Cisplatin (45 mg/m^2) dissolved in 20 mg 0.9% sodium chloride for intravenous injection	①, ②, ④, ⑨, ⑩,
Jiang M. 2018	China	Non-small-cell lung cancer	IV	52	24	28	33/19	First-line treatment	Bevacizumab (5 mg/kg) + saline (20 mL) was administered once every 7 days via central venous catheter by thoracic infusion for 3 consecutive doses	Carboplatin injection (300 mg) + saline (50 mL) via central venous catheter for thoracic infusion	①, ②, ③, ④, ⑥, ⑦, ⑧, ⑨,
Ang Bing 2018	China	Non-small-cell lung cancer	IV	27	14	13	15/12	First-line treatment	Bevacizumab (200 mg) + cisplatin (60 mg/m^2) by intrathoracic infusion, d1, 2 times/week for 3 weeks	Cisplatin (60 mg/m^2) by intrathoracic infusion	①, ②, ③, ④, ⑤, ⑥, ⑦, ⑧
Qu B. 2015	China	Non-small-cell lung cancer	IV	63	32	31	36/27	First-line treatment	Bevacizumab (5 mg/kg) + cisplatin (40 mg/m^2) by intrathoracic infusion, 1 time/week, 3 cycles	Cisplatin (40 mg/m^2) by intrathoracic infusion	(①, ②, ③, ④, ⑤, ⑥, ⑦, ⑧
Lin F. H. 2016	China	Non-small-cell lung cancer	IV	94	47	47	50/44	First-line treatment	Bevacizumab (5 mg/kg) + cisplatin (45 mg/m^2), dissolved in 20 ml of saline and injected into the chest cavity through a central venous catheter once a week for 3 weeks	Cisplatin (45 mg/m^2) dissolved in 20 ml saline for intrathoracic instillation	①, ②, ③, ④, ⑨, ⑩, ⑪
Xue D. F. 2017	China	Non-small-cell lung cancer	IV	82	41	41	47/35	First-line treatment	Bevacizumab (5 mg/kg) + cisplatin (60 mg) by intrathoracic infusion, once a week for 3 weeks	Cisplatin (60 mg) by intrathoracic infusion	(①, ②, ③, ④, ⑤
Chen L. 2015	China	Non-small-cell lung cancer	IV	54	28	26	27/17	First-line treatment	Bevacizumab, (5 mg/kg) + cisplatin (75 mg/m^2) by intrathoracic infusion, divided into 2 cycles of 21 d each	Cisplatin (75 mg/m^2) by intrathoracic infusion	①, ②, ④, ⑦, ⑧, ⑩

Note. ① CR, complete remission; ② PR, partial remission; ③ leukopenia; ④ nausea and vomiting; ⑤ diarrhea; ⑥ rhinorrhea; hemoptysis or gastrointestinal bleeding; ⑦ elevated blood pressure; ⑧ proteinuria; ⑨ abnormal liver and kidney function; ⑩ heart rate disorders; ⑪ skin rash.